An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.
Colorectal Cancer
Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events, approximately 15 months
Proportion of patients with treatment discontinuation due to other causes, approximately 15 months|Incidence of other causes for treatment discontinuation, approximately 15 months|Second-line treatments initiated, approximately 15 months|Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes), approximately 15 months
This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.